Home/Pipeline/BIIB080 / BIIB113 (Tau ASO)

BIIB080 / BIIB113 (Tau ASO)

Alzheimer's Disease

Phase 2ActiveN/A

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 2

Status

Active

Company

Biogen

About Biogen

Founded in 1978, Biogen has established itself as a cornerstone of the biotechnology industry, renowned for pioneering multiple sclerosis treatments and launching the first approved therapy for Alzheimer's disease. The company's strategy is anchored in a focused R&D engine that reinvests approximately $2 billion annually into neurology, immunology, and rare disease pipelines, balancing bold scientific risk with disciplined capital allocation. Its mission is to translate cutting-edge science into transformative medicines, creating value for patients, shareholders, and communities.

View full company profile

Therapeutic Areas

Neurology Immunology Rare Diseases

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
itMSCs	Stemedica Cell Technologies	Clinical Development	Active
Aucuba-001	Aucuba Sciences	Preclinical	Active
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
NTRX-07	NeuroTherapia	Phase 2	Active
3D Neuronal Disease Models	BioTalentum	Research	Active
Not Publicly Disclosed	Cerecin	Phase 1/2	Active